06-05-2020, 11:57 PM
(This post was last modified: 06-06-2020, 12:06 AM by BostonCard.)
Now back to our regularly scheduled program evaluating the efficacy of hydroxychloroquine for COVID-19.
https://www.recoverytrial.net/news/state...h-covid-19
The RECOVERY trial was one of several trials looking at multiple possible treatments for COVID-19 against placebo, in this case, in addition to hydroxychloroquine, they looked a:
[full disclosure, I work for the company that makes tocilizumab and thus cannot talk about it, but I was not involved in this study]
The full results of the analysis haven't been published. This was an interim analysis by the data safety monitoring board (DSMB), which will look at the data and can stop the trial or an arm of the trial early if there is either overwhelming evidence of benefit, or evidence of futility. In this case, they stopped the hydroxychloroquine arm for evidence of futility.
As much as I would love for hydroxychloroquine to work, accumulating evidence suggests that it does not.
BC
Should add, the DSMC for the WHO Solidarity trial also met, and it concluded that the hydroxchloroquine arm could resume and there was no need to halt the trial.
https://www.who.int/emergencies/diseases...treatments
BC
https://www.recoverytrial.net/news/state...h-covid-19
The RECOVERY trial was one of several trials looking at multiple possible treatments for COVID-19 against placebo, in this case, in addition to hydroxychloroquine, they looked a:
- Lopinavir-Ritonavir (commonly used to treat HIV)
- Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation)
- Azithromycin (a commonly used antibiotic)
- Tocilizumab (an anti-inflammatory treatment given by injection)
- Convalescent plasma (collected from donors who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus).
[full disclosure, I work for the company that makes tocilizumab and thus cannot talk about it, but I was not involved in this study]
The full results of the analysis haven't been published. This was an interim analysis by the data safety monitoring board (DSMB), which will look at the data and can stop the trial or an arm of the trial early if there is either overwhelming evidence of benefit, or evidence of futility. In this case, they stopped the hydroxychloroquine arm for evidence of futility.
Quote:‘A total of 1542 patients were randomised to hydroxychloroquine and compared with 3132 patients randomised to usual care alone. There was no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes.
As much as I would love for hydroxychloroquine to work, accumulating evidence suggests that it does not.
BC
Should add, the DSMC for the WHO Solidarity trial also met, and it concluded that the hydroxchloroquine arm could resume and there was no need to halt the trial.
https://www.who.int/emergencies/diseases...treatments
Quote:Originally posted 27 May 2020, updated 4 June 2020
Having met on 23 May 2020, the Executive Group of the Solidarity Trial decided to implement a temporary pause of the hydroxychloroquine arm of the trial, because of concerns raised about the safety of the drug. This decision was taken as a precaution while the safety data were reviewed by the Data Safety and Monitoring Committee of the Solidarity Trial.
On 3 June 2020, WHO's Director-General announced that on the basis of the available mortality data, the members of the committee have recommended that there are no reasons to modify the trial protocol.
The Executive Group received this recommendation and endorsed the continuation of all arms of the Solidarity Trial, including hydroxychloroquine.
The Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the Solidarity Trial.
BC